Triple therapy for chronic obstructive pulmonary disease: Trials catching up with clinical practice?

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 8, 2009, Pages 689-690

  Jones, Paul W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUTICASONE; FORMOTEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE EXACERBATION; EDITORIAL; EMERGENCY HEALTH SERVICE; FORCED EXPIRATORY VOLUME; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 70349883780     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200908-1205ED     Document Type: Editorial

References (12)

1. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-750.
2. Aaron SD, Vandemheen KL, Ferguson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell DE, McIvor A, Sharma S, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555. (Pubitemid 351650535)
3. Donohue JF. Minimally clinically important differences in COPD lung function. COPD 2005;2:111-124.
4. Calverley PMA, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919. (Pubitemid 37540641)
5. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. (Pubitemid 36150304)
6. Calverley PMA, Pauwels R, Vestbo J, Jones PW, Pride N, Gulsvick A. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. Lancet 2003;361:449.
7. Calverley PM, Anderson JA, Celli BR, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. Salmeterol and fluticasone proprionate and survival in chronic obstructive pulmonary disease. N Engl JMed 2007; 356:775-789. (Pubitemid 46294610)
8. Ferguson GT, Anzuetto A, Fei R, Emmett A, Knobil K, Karlberg C. Effect of fluticasone proprionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respir Med 2008;102:1099-1108.
9. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2009 [Accessed Aug 4 2009]. Available from: http://www.goldcopd.com/GuidelinesResources.asp
10. Jenkins CR, Jones PW, Calverley PMA, Celli BR, Anderson JA, Ferguson GT, Yates JC, Willets LR, Vestbo J. Efficacy of salmeterol/fluticasone proprionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59.
11. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303. (Pubitemid 30245717)
12. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880-887 (Pubitemid 32999838)